Clinical trial NCT01212744: Safety, Tolerability, and Efficacy Study of rAvPAL-PEG Administered Daily in Subjects With Phenylketonuria (PKU)
Official title: A Phase 2, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Dose Levels of rAvPAL-PEG Administered Daily in Subjects With Phenylketonuria
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Phenylketonuria
Keywords: PEG PAL; PKU; injection;
Lead sponsor: BioMarin Pharmaceutical
Sponsor class: INDUSTRY
First posted: 2010-10-01
Enrollment: 16
Sex: ALL
Minimum age (years): 16
Maximum age (years): 70
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the effect of daily administration of rAvPAL-PEG on the reduction of blood Phe concentrations in subjects with PKU.

Detailed description: This 16-week multi-center, open-label, Phase 2 study is designed to evaluate the safety, tolerability,and efficacy of daily SC injections of rAvPAL-PEG in subjects with PKU. Subjects who are naïve to prior treatment with rAvPAL-PEG and who have met the other study eligibility criteria will be enrolled at approximately 8 sites in the US and Canada. Up to 6 daily dose levels of rAvPAL-PEG are planned and may be assessed during this study (0.06 mg/kg/day, 0.1 mg/kg/day, 0.2 mg/kg/day;0.4 mg/kg/day, 0.6 mg/kg/day, or 0.8 mg/kg/day). Enrollment will begin with the 0.4 mg/kg/day dose level and additional higher or lower doses may be added. The additional dose levels chosen for assessment will be based on the safety (systemic reaction or clinically significant abnormal laboratory test results assessed as related to study drug) and efficacy (blood Phe reduction to less than or equal to 60 μmol/L) information of at least 3 subjects with at least 2 weeks of daily dosing with rAvPAL-PEG. Initiation of dosing at higher or lower dose levels will be per the determination of the Sponsor's Medical Officer in consultation with the Investigator.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of PKU with both of the following: current blood Phe concentration of ≥ 600 micromol/L at screening and average blood Phe concentration of ≥ 600 micromol/L over the past 3 years, using available data
* Evidence that the subject is a non-responder to Kuvan® treatment (ie, 4 weeks of treatment with 20 mg/kg/day of Kuvan, insufficient response per investigator determination, and treatment end date ≥ 14 days prior to Day 1 \[ie, first dose\]). Subjects who have had a previous response to Kuvan® treatment but are not currently taking Kuvan® because of noncompliance and have been off treatment for ≥ 4 months prior to screening are eligible for participation.
* Willing and able to provide written, signed informed consent, or, in the case of participants under the age of 18, provide written assent (if required) and written informed consent by a legally authorized representative, after the nature of the study has been explained, and prior to any research-related procedures.
* Willing and able to comply with all study procedures.
* Between the ages of 16 and 70 years, inclusive.
* Negative pregnancy test at screening and willing to have additional pregnancy tests performed during the study for females of childbearing potential only. Females considered not of childbearing potential are those who have been in menopause for at least 2 years or have had a tubal ligation at least 1 year prior to screening, or who have had a total hysterectomy.
* Willing to use an acceptable method of contraception while participating in the study (sexually active subjects only).
* Maintained a stable diet with no significant modifications during the 4 weeks preceding the administration of study drug.
* In generally good health as evidenced by physical examination, clinical laboratory evaluations (hematology, chemistry, and urinalysis), and ECG at screening.

Exclusion Criteria:

* Prior use of rAvPAL-PEG.
* Use of any investigational product or investigational medical device within 30 days prior to screening, or requirement for any investigational agent prior to completion of all scheduled study assessments.
* Use of any medication that is intended to treat PKU within 14 days prior to the administration of study drug.
* Use or planned use of any injectable drugs containing PEG (other than rAvPAL-PEG), including Depo-Provera, within 3 months prior to screening and during study participation.
* Known hypersensitivity to rAvPAL-PEG excipients.
* Breastfeeding at screening or planning to become pregnant (self or partner) or to breastfeed at any time during the study.
* Concurrent disease or condition that would interfere with study participation or safety (eg, history or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurological, oncologic, or psychiatric disease).
* Any condition that, in the view of the investigator, places the subject at high risk of poor treatment compliance or of not completing the study.
* Alanine aminotransferase (ALT) concentration \> 2 times the upper limit of normal.
* Creatinine \> 1.5 times the upper limit of normal.

Primary outcomes:
measure: Blood Phenylalanine Concentration
timeFrame: Baseline, Week 16
Secondary outcomes:
measure: Study Drug Related Adverse Events
timeFrame: Weekly
measure: Percentage of Participants With PAL IgG Antibody Percentage of Participants With Positive PAL IgG
timeFrame: Baseline, Week 16
measure: Plasma Concentrations of rAvPAL-PEG (BMN 165)
timeFrame: Baseline, Week 8, Week 13
measure: Percentage of Participants With PEG-IgG Antibody Positivity
timeFrame: Baseline, Week 16
measure: Percentage of Participants With PAL-IgM Antibody Positivity
timeFrame: Baseline, Week 16
measure: Percentage of Participants With PEG-IgM Antibody Positivity
timeFrame: Baseline, Week 16
measure: Percentage of Participants With Neutralizing Antibody Positivity
timeFrame: Baseline, Week 16
measure: Percentage of Participants With PAL-IgE Antibody Positivity
timeFrame: Baseline, Week 16
measure: Percentage of Participants With PAL-PEG-IgE Antibody Positivity
timeFrame: Baseline, Week 16
Other outcomes:
Locations:
city: Aurora
country: United States
facility: The Children's Hospital
state: Colorado
city: Gainesville
country: United States
facility: University of Florida
state: Florida
city: Louisville
country: United States
facility: Weisskopf Child Evaluation Center / University of Louisville
state: Kentucky
city: Columbia
country: United States
facility: University of Missouri
state: Missouri
city: Saint Louis
country: United States
facility: Washington University Center for Applied Research Sciences
state: Missouri
city: Albany
country: United States
facility: Albany Medical Center
state: New York
city: Columbus
country: United States
facility: Nationwide Children's Hospital
state: Ohio
city: Pittsburgh
country: United States
facility: University of Pittsburgh Medical Center
state: Pennsylvania
city: Madison
country: United States
facility: University of Wisconsin-Madison
state: Wisconsin
Study officials:
affiliation: BioMarin Pharmaceutical
name: Ari Gershman, MD
role: STUDY_DIRECTOR
References:
citation: Burton BK, Longo N, Vockley J, Grange DK, Harding CO, Decker C, Li M, Lau K, Rosen O, Larimore K, Thomas J; PAL-002 and PAL-004 Investigators. Pegvaliase for the treatment of phenylketonuria: Results of the phase 2 dose-finding studies with long-term follow-up. Mol Genet Metab. 2020 Aug;130(4):239-246. doi: 10.1016/j.ymgme.2020.06.006. Epub 2020 Jun 16.